**Chapter 11**

**Beyond Contraception: The Multifaceted Landscape of Intrauterine Devices (IUDs)**

Dr. Bishwanath Mishra 1,\*, Dr. Brijesh Shivhare 2, Bindu Singh yadav 3, Kamalesh Mistry 4, Dr. Ujashkumar Shah 5

*1* *Assistant Professor, Institute of Pharmacy & Technology, Salipur, At/Po-Salipur, Dist-Cuttack, Odisha 754202*

*2 Assistant Professor, Department of Bioscience, Faculty of Science, P.K. University, Shivpuri, Madhya Pradesh -473665*

3 *Assistant Professor, Department of Pharmacology, Goel institute of pharmacy and science - 226028*

*4 Assistant Professor, Department of Pharmacognosy, School of Pharmacy, Rai University, SH-144, Saroda, Dholka, Ahmedabad, 382260, Gujarat, India.*

*5 Professor and Head, Nootan Pharmacy College, Sankalchand Patel University, SK campus, Visnagar, Gujarat-384315*

**\*Corresponding Author**

Dr. Bishwanath Mishra

*Assistant Professor, Institute of Pharmacy & Technology, Salipur, At/Po-Salipur, Dist-Cuttack, Odisha 754202*

**Abstract**

This Book chapter exploration delves into the multifaceted realm of Intrauterine Devices (IUDs), tracing their developmental trajectory and examining their diverse applications in reproductive healthcare. The paper begins by elucidating the historical evolution of IUDs, shedding light on the pivotal milestones that have shaped their design and usage over time. A thorough analysis of the advantages and disadvantages associated with IUDs follows, addressing both clinical efficacy and patient perspectives. The chapter also highlights the various applications of IUDs beyond contraception, exploring their roles in managing gynecological conditions, such as heavy menstrual bleeding and endometriosis. Furthermore, the chapter discusses emerging trends in IUD research and development, including innovations aimed at enhancing user experience and expanding their applicability. The synthesis of historical context, clinical insights, and forward-looking perspectives offers a comprehensive overview of Intrauterine Devices, contributing to a nuanced understanding of their significance in modern reproductive healthcare. This chapter aims to inform healthcare professionals, researchers, and the general public about the evolving landscape of IUDs, encouraging further dialogue and research in this critical field.

**KEYWORDS:** *IUD, Gynecological Health, Reproductive health, Healthcare*

**Background and Rationale Study:**

In recent decades, Intrauterine Devices (IUDs) have emerged as a cornerstone in the field of reproductive healthcare, offering a highly effective and reversible method of contraception. The development and evolution of IUDs have witnessed significant advancements, shaped by both medical and societal factors. Understanding the historical context and rationale behind the continuous refinement of these devices is essential for comprehending their present significance and future potential. Historically, the concept of intrauterine contraception dates back centuries, with early forms of rudimentary devices documented as far back as ancient times. The modern era, however, witnessed a transformative shift in the development of IUDs, marked by the introduction of copper-based and hormonal variations. These innovations aimed not only to enhance contraceptive efficacy but also to address previous concerns and side effects associated with earlier iterations. The rationale for the persistent exploration and improvement of IUDs lies in their unique advantages and versatility. Unlike some other contraceptive methods, IUDs offer long-term protection with a single insertion, reducing the risk of user error. Furthermore, they are reversible, allowing individuals to regain fertility promptly upon removal. The potential for broader applications beyond contraception, such as managing gynecological conditions and addressing global health disparities, adds layers of significance to the ongoing research and development in this field.

Despite the numerous advantages, it is crucial to acknowledge the existing disadvantages and misconceptions surrounding IUDs. Addressing concerns related to insertion discomfort, potential side effects, and misconceptions about their safety is essential for promoting informed decision-making among healthcare providers and individuals. This chapter seeks to comprehensively explore the development of IUDs, providing a historical perspective on their evolution. By critically evaluating the advantages and disadvantages associated with IUD usage, the study aims to offer a balanced understanding of their clinical utility. Furthermore, by investigating the diverse applications of IUDs, from contraception to therapeutic use, this chapter contributes to the broader discourse on improving reproductive healthcare. The background and rationale study, therefore, sets the stage for a detailed examination of the multifaceted landscape of Intrauterine Devices, guiding future research and clinical practice in this crucial area of women's health.

**Recent Advancements in the Field of Intrauterine Devices (IUDs):**

**1. Next-Generation Materials and Designs:**

Recent developments in materials science and engineering have led to the exploration of novel materials for IUDs. Innovations in materials such as bio-compatible polymers aim to improve user comfort, reduce side effects, and enhance the overall effectiveness of IUDs. Additionally, advancements in device design, including shape and size modifications, contribute to increased ease of insertion and minimized discomfort.

**2. Hormonal IUDs with Extended Durations:**

Ongoing research has focused on extending the duration of hormonal IUD effectiveness. New formulations and delivery systems are being investigated to prolong the release of hormones, potentially offering contraceptive protection for an even more extended period, thus reducing the frequency of device replacements and improving user convenience.

**3. User-Centric Approaches and Customization:**

Recent advancements prioritize user preferences and experiences, leading to the development of customizable IUDs. Tailoring the device to individual needs, such as adjusting hormone levels or adapting to specific health conditions, reflects a more personalized and patient-centric approach to contraception and reproductive health.

**4. Digital Integration for Monitoring and Management:**

Integration of digital technologies into IUDs has gained attention, allowing for real-time monitoring and management. Smart IUDs equipped with sensors or connectivity features enable healthcare professionals and users to track usage, detect anomalies, and receive timely alerts, enhancing both safety and user engagement.

**5. Expanded Applications for Gynecological Health:**

Beyond contraception, recent advancements explore the therapeutic applications of IUDs in managing various gynecological conditions. Studies are underway to evaluate their efficacy in treating conditions such as endometriosis, adenomyosis, and heavy menstrual bleeding. This expansion of applications broadens the potential impact of IUDs on women's health.

**6. Global Health Initiatives and Access:**

Efforts to improve global access to IUDs have seen advancements in low-cost, easily deployable devices suitable for diverse healthcare settings. Initiatives focus on overcoming barriers to access, including affordability, cultural considerations, and logistical challenges, aiming to make IUDs a more accessible and viable option for women worldwide.

**7. Fertility Awareness Integration:**

Advancements in fertility tracking and awareness have been integrated into some IUD designs. By incorporating features that enable users to monitor their fertility and plan contraception accordingly, these devices provide a holistic approach to reproductive health, empowering individuals to make informed decisions about family planning.

These recent advancements collectively contribute to the ongoing evolution of Intrauterine Devices, reflecting a commitment to improving their safety, effectiveness, and applicability across diverse healthcare contexts. Continued research and innovation in these areas hold the promise of further enhancing the role of IUDs in women's reproductive health and family planning.


**KEY QUESTIONS:**

1. **INTRODUCTION**

Globally, the intrauterine device (IUD) is the prevailing reversible form of family planning. Copper or levonorgestrel-releasing products have mostly supplanted the older, non-reactive plastic IUDs in contemporary medical practice. These enhancements significantly enhance the already outstanding effectiveness of the product. More than 50,000 women participated in 34 randomized controlled studies comparing various devices; the results showed that copper IUDs effectively prevented pregnancies, with the TCu380A providing protection for as long as 12 years [1]. When compared to other devices like the Multiload 375 (MLCu375), Multiload 250 (MLCu250), Copper T220 (TCu220), and Copper T200 (TCu200), the TCu380A exhibited superior performance. The levonorgestrel intrauterine system (LNG-IUS) demonstrated reduced pregnancy rates compared to copper devices in two examinations. Both the LNG-IUS and copper IUDs share comparable risk factors for side effects and device-related issues, including as perforations and expulsions. Correct insertion helps prevent complications such as perforations, expulsions, and pain. In the first three months following insertion, most frequently during menstruation, 1 out of every twenty women will experience the expulsion of an intrauterine device (IUD) [2]. The most severe adverse effects, including severe dysmenorrhea and bleeding, cause 10% of women to remove their copper intrauterine devices (IUDs) after the first year of use [3]. One out of every twenty pregnancies that occur with an IUD in situ are ectopic, suggesting that the IUD mostly prevents pregnancies that develop within the uterus [4]. However, the incidence of ectopic pregnancies is reduced in women who use intrauterine devices (IUDs) (0.1% in 5 years compared to no contraception). Up to 50% of women who use intrauterine devices (IUDs) stop using them within 5 years due to unacceptable vaginal bleeding or pain [2]. Concerning bleeding concerns, such as amenorrhea, 14% of copper T users and 11% of LNG-IUS users require removals after 36 months of use [5]. In contrast to copper IUDs, the LNG-IUS affects menstruation rhythm in a unique way. Copper IUDs are associated with dysmenorrhea and an increase in monthly volume, in contrast to the LNG-IUS, which is associated with reduced flow and less painful menstruation [6]. The first few months of LNG-IUS treatment are typically the most common time for patients to encounter irregular bleeding or spotting. After the endometrial effects of LNG-IUS have been established, the bleeding pattern changes to oligomenorrhea or amenorrhea. After one year of using LNG-IUS, 20% of women will have met the strict criteria for amenorrhea (90 days without bleeding or spotting). Only women with severe cramping or extensive bleeding during periods may be administered the LNG-IUS because to its fivefold higher price tag, lower menstrual flow, and equal effectiveness to high dose copper devices [1]. There is a wide disparity in the global fertility rate, with the industrialized world boasting 4.6 children per woman and the poor world boasting just 1.7. With 4.5 children per woman being the average fertility rate. If poor countries want to bring the world's reproduction rate down, they need therapies like intrauterine devices (IUDs) that work and last [7,8,9]. In 2012, unintended pregnancies accounted for 40% of all pregnancies, with 50% ending in abortions and 20% in miscarriages [10]. Both the mother and the child suffer socially and medically as a result of the high incidence of unwanted births, which is largely attributable to the inconsistency or misuse of contraceptives such intrauterine devices (IUDs) [11,12,13]. Plus, there's proof that IUDs reduce abortion rates, unplanned pregnancies, and maternal mortality and morbidity when they're used properly. The use of intrauterine devices (IUDs) by all women without access to other forms of birth control could prevent 24 million abortions, 6 million miscarriages, 70,000 maternal deaths, and 500,000 child deaths globally [14, 15]. Among reproductive-age women around the world, intrauterine devices (IUDs) have gained widespread recognition as an effective, modern, and reversible long-term form of birth control [16, 17]. The usage of intrauterine devices (IUDs) was lowest, with only 2% of women utilizing them, whereas insertion-based contraceptives were the most common [18]. Improving IUD utilization can be achieved through a variety of means, such as health facility-level education on the device, clear and concise communication to allay community misconceptions, and thorough counseling on contraceptive usage [19]. There is a connection between these elements and the features of healthcare providers, the health system, and the user themselves [20, 21].

**Mechanism of Action**

The precise process by which rings and other objects inserted into the uterus of humans and other animals might inhibit conception has remained a mystery for more than two millennia [22]. To investigate how IUDs work, researchers have struggled to locate an appropriate animal model [23]. This is so even though, as one might expect, they trigger a mild inflammatory response that involves the infiltration of white blood cells into the endometrium. The results are often inconclusive, and ethical concerns always limit research including female subjects. Furthermore, intrauterine contraception is not always a poor choice [24]. The main approach is shown in Figure 1.



**Figure 1:** Efficacy of intrauterine devices

**Possible locations where IUDs can exert their effects**

All four major phases of fertilization—ovulation, sperm transit, and implantation—have had their impact on the effectiveness of the intrauterine device (IUD).

**Ovulation refers to the release of a mature egg from the ovary**


Ostrovational cycles are frequent for women who use intrauterine devices (IUDs). Despite the fact that women who have used LNG-IUS for a long time have levonorgestrel levels in their bloodstream that are similar to those of Norplant users, there is no proof that the inhibitory effect of LNG-IUS on ovulation is the cause of its contraceptive effects [25].

**Transport and functionality of sperm**

In less than an hour, spermatozoa leave the cervix and make their way to the fallopian tube and the peritoneal cavity. The number of fertilized eggs discovered in the ampullary portion of the fallopian tube decreases in women who use copper IUDs or the LNG-IUS [26,27]. In contrast to copper ions, which are poisonous to spermatozoa [28], high levels of levonorgestrel alter the properties of cervical mucus, making it unsuitable for sperm to pass through [29,30]. Thus, it seems that those who use IUDs or IUSs have a decrease in the amount and quality of sperm that make it to the fallopian tube, where fertilization takes place. On rare occasions, fertilization fails, which raises the question of whether there is a problem with the capacity to fertilize the egg with the few high-quality sperm that make it into the tube. Analyzing the effect of oocyte quality on fertilization By removing oocytes and pre-implantation embryos from the uterus and fallopian tubes of women who have undergone surgical sterilization, some studies have attempted to ascertain the frequency of fertilization and the typical maturation of the ovum [22,23]. Due to the high level of technical expertise required for the research, sample numbers are consistently kept small. The typical development of fertilized eggs in the Fallopian tube was not observed in women who used copper intrauterine devices (IUDs), in contrast to women who used inert or LNG filled IUDs or who did not use IUDs, according to a highly cited study [31]. The failure rates of intrauterine devices (IUDs), a kind of very effective contraception, are equivalent to those of other sterilization methods [32]. Among American women, you may find intrauterine devices (IUDs) that contain either levonorgestrel or copper. The success rates of the two methods in preventing pregnancy are similar, at 0.08% and 0.02%, respectively. When it comes to preventing pregnancy, these devices have an efficacy rate of above 99% [33]. The use of LARCs, or long-acting reversible contraception, has increased in the US since 1995. Over the years, the percentage of women who use LARC has steadily increased, and now 14% of all women use LARC [32]. There has been a decrease in undesired pregnancies as a result of the increased use of LARC [32]. In addition, intrauterine devices (IUDs) have many benefits, including high effectiveness, ease of use, reversibility, and high patient satisfaction, especially when considering the long-term commitment and expense [34].

**Study of the structure and function of living organisms**

Presently available intrauterine devices (IUDs) in the US all include a T-shaped design, with the top half of the T placed across the top half of the endometrial cavity. The standard dimensions for an intrauterine device (IUD) are a length of 30–36 mm and a breadth of 28–32 mm. Conventional wisdom holds that all patients can get by with just a wide uterus. Ultrasound studies have recently revealed, however, that a woman's uterus canal may be narrower than the breadth of some devices even before she gives birth [35]. Hence, it is crucial to take into account the many IUD options that are accessible. The smallest intrauterine devices (IUDs) are ideal for younger women and those who have not given birth yet because their dimensions are only 28 mm wide and 30 mm long. During the process of IUD insertion and removal, it is crucial to accurately locate the cervix and uterus, which serve as the main anatomical reference points. The bimanual examination will be performed to identify the uterus and evaluate its dimensions, morphology, orientation, and detect any structural irregularities [36]. The cervix will be detected through the process of speculum examination [36]. **Figure 2.** displays various variations of intrauterine devices (IUDs).



**Figure 2:** Two different types of IUD

**Signs or symptoms that suggest the presence or occurrence of a particular condition or disease.**

Two main varieties of intrauterine devices (IUDs) exist: those that contain levonorgestrel and those that contain copper. That is why it is so important to know when to use each of these IUDs. It is highly recommended to use an intrauterine device (IUD) just for the purpose of preventing pregnancy. Choose between three different dosages of the intrauterine device (IUD) that contains levonorgestrel: 13.5 mg, 19.5 mg, and 52 mg. When it comes to providing reliable birth control, they are all on par [37]. For menorrhagia management and endometrial protection during hormone replacement therapy, the 52 mg intrauterine device (IUD) is approved [38, 39]. Among the intrauterine devices (IUDs), the 13.5 mg IUD has a 3-year maximum authorization period, while the 19.5 mg and 52 mg IUDs have 5-year maximum authorization periods [37]. One copper intrauterine device (IUD) can be used for birth control for up to ten years. However, there is a well-established off-label use for this to be used as an emergency method of birth control for up to five days after an unprotected sexual encounter. It is believed that approximately 0.1% of emergency contraceptives fail after placement [40]. One option is to attach the intrauterine device (IUD) immediately after giving birth, within 10 minutes of the placenta being delivered. Another option is to wait 4-6 weeks after giving birth to insert the IUD. Assuming the abortion was not a septic one, they can be implanted even after the fact [41,42]. The removal of the intrauterine device (IUD) is often indicated for other reasons. The patient's desire to have a baby, abnormal or heavy menstrual bleeding, or pain or discomfort that could be caused by the device moving about are some of the reasons why patients choose to have their devices removed [43]. The patient wanted the IUD removed because she experienced bleeding abnormalities, especially heavier bleeding, more frequently with the copper-containing IUDs than with the levonorgestrel-IUDs [44]. The presence of a pregnancy inside the uterus is another reason for expulsion. However, any device that enters the uterine cavity should not be removed unless the strings are visible or easily detected inside the cervical region [45]. There is a forty-five to fifty percent increase in the probability of spontaneous abortion when the intrauterine device (IUD) is retained. There is no risk of teratogenesis associated with keeping the IUD in place. In such cases, the risk of spontaneous abortion drops to 20% after removing the intrauterine device (IUD) [45]. Cervical or uterine cancer, jaundice, or another medical condition are further grounds for removing the intrauterine device (IUD) containing levonorgestrel [46]. You should take the device out of your body if it has been there for longer than the allowed effectiveness period. The 19.5 mg and 52 mg devices have a 5-year authorized duration. Three years is the suggested duration for the 13.5 mg device. Ten years is the authorized term for specific individuals. Permitted durations are subject to regular modifications; for the most up-to-date prescribing information, please refer to the package insert of each individual medicine.

**Contraindications**

Since two distinct types of intrauterine devices (IUDs) are available, it's important to be aware of the specific risks associated with each. There are, however, common contraindications that govern both varieties.

**The IUD has universal contraindications [47].**

• Gestation or suspected gestation

• The presence of a sexually transmitted infection during insertion, such as inflammation of the cervix (cervicitis), inflammation of the vagina (vaginitis), or any other infection in the lower part of the reproductive system.

• A congenital uterine defect that leads to the distortion of the uterine cavity, making implantation difficult.

• Acute pelvic inflammatory disease.

• Prior instance of pelvic inflammatory illness, unless there has been a subsequent viable pregnancy within the uterus.

• History of septic abortion or postpartum endometritis in the past 3 months.

• Presence of confirmed or suspected uterine or cervical malignancy/neoplasia.

• Unaccounted for anomalous uterine hemorrhage • Any circumstance that increases the likelihood of acquiring a pelvic infection

• Prior utilization of an intrauterine device (IUD) that remains in place • Excessive susceptibility to any component of the device.

**The levonorgestrel intrauterine device (IUD) has additional contraindications, such as [47]:**

• Any cancer that is sensitive to progestin, including benign breast tumors, whether they have been diagnosed or not.

• Hepatic neoplasms, either benign or malignant in nature

• Acute hepatic disorder

**Here are some more reasons why the copper IUD shouldn't be used [47]:**

•Wilson disease

• Copper sensitivity

**Equipment** remains essentially the same regardless of the specific intrauterine device (IUD) being used or removed, with the exception of the specific IUD being inserted. The necessary apparatus for conducting IUD insertion comprises:

• Two pairs of gloves, with one pair being sterile

• A sterile uterine sound

• A sterile tenaculum

• An intrauterine device (IUD) in a sterile container

• Anesthesia and all the necessary supplies for a paracervical block

• A sterile sharp

• Long-handled scissors


Gloves, a speculum, sterile forceps, and a cytobrush are the essential instruments for inserting and removing an intrauterine device (IUD) [36].

**Staff**

In order to ensure a successful placement or removal of an IUD, it is imperative that the healthcare professional conducting the process is adequately trained in the use of the specific inserters and is proficient in the numerous techniques involved. Manufacturers of various intrauterine devices (IUDs) give training for healthcare providers and offer a diverse array of materials on their own websites. It would also be advantageous to have at least one more individual there to assist with the distribution of the required items. Improper implantation of the device by an inexperienced practitioner may result in displacement and uterine perforation, posing a significant risk.

**Preparation**

It is crucial to provide thorough counseling on the various methods of birth control before beginning an intrauterine device (IUD). It is important to advise patients that long-acting reversible contraception (LARC) is very successful in preventing conception. This includes intrauterine devices (IUDs) and subdermal implants. When compared to tubal ligation and vasectomy, their efficacy is on par [48]. In addition, there is strong evidence that the main strategy for reducing teen pregnancies should be long-acting reversible contraception (LARC). The safety of intrauterine devices (IUDs) in this particular age range has also been proven [49]. To promote the use of Long-Acting Reversible Contraceptives (LARCs), the Contraceptive CHOICE initiative studied their effectiveness and worked to increase patients' familiarity with and comfort with using them. By making the gadgets available at no cost, the project has also removed a financial barrier [50]. After these barriers were removed, almost 66% of the women in this study opted for LARC techniques, which include intrauterine devices (IUDs) and subdermal implants [50]. As a result, all patients who are able to use intrauterine devices (IUDs) should get counseling on the benefits of using them. In the end, it's up to the patient to decide which kind of birth control will work best for them. After a patient has decided on a device, the next step is for the office to acquire it, check the patient's insurance, and/or gain prior approval for the device and its installation. Intrauterine devices (IUDs) created in the 1990s are shown in Figure 3.



**Figure 3:** IUDs first appeared in the 1990s

There are a number of ways to get a patient ready for an intrauterine device (IUD) insertion operation after they've decided it's the best method of birth control for them. It is critical to confirm a negative pregnancy test before beginning the surgery. Patients are more likely to comply with treatment plans and the risk of unwanted pregnancies is lower when the fast start method allows for instant counseling and insertion [51]. But this isn't always an option when a doctor can't confirm a negative pregnancy test since the patient has recently engaged in sexual activity without protection or a modern method of birth control. In order for a pregnancy test to provide accurate results, it is necessary to fulfill one of the following conditions [52]:

• Within one week of the first day of a typical menstrual period

• Since the beginning of the most recent period, you have not engaged in sexual activity

• Relying on an alternate form of birth control on a regular basis • Within one week after a natural or artificial abortion

• Four weeks after giving birth

• Engaged in exclusive or near-exclusive nursing, experiencing amenorrhea, and fewer than six months after giving birth

If these criteria are not met, it is deemed suitable to offer the patient a non-implantable form of contraception, such as oral contraceptives, vaginal rings, transdermal patches, condoms, or medroxyprogesterone acetate injections [50]. Should the patient persist in pursuing LARC insertion subsequent to commencing one of these bridging methods, a follow-up pregnancy test can be conducted within a span of 3-4 weeks. In the event of a negative test result, the patient is able to proceed with LARC installation [50]. Upon insertion of a copper IUD, the previous method of birth control can be discontinued, as the IUD promptly becomes effective. However, if the levonorgestrel intrauterine device (IUD) is not put within 7 days following the start of menstruation, it is advised to use an additional form of contraception for a duration of 7 days [52].

Moreover, if deemed essential, it is imperative to perform a comprehensive assessment for sexually transmitted diseases, while considering the patient's sexual background. Women who have not received screening for sexually transmitted infections should have screening during insertion if it is advised by recommendations. Nevertheless, the presence of this factor should not result in any postponement of the device's implementation [44]. When a patient tests positive for an infection after getting an IUD, it is advised to give antibiotics for therapy while keeping the IUD in place [44]. Patients with a concurrent infection after insertion are exposed to a modest risk, around 0.1%, of developing pelvic inflammatory disease. However, it is crucial to avoid detaching the device [53]. If a patient is found to have cervical discharge containing pus or if the physical examination indicates an ongoing infection, the insertion of the intrauterine device (IUD) should be postponed, and the patient should be given suitable treatment [47].

Once counseling has been confirmed and a negative pregnancy test has been obtained, the next step is to obtain informed consent. The procedure requires a thorough discussion of the potential risks, benefits, and negative outcomes for the patient. Possible risks to the patient include discomfort during insertion, uterine perforation that may necessitate surgery or lead to unintended pregnancy, infection, bleeding at the insertion site, unnoticed expulsion resulting in unintended pregnancy, and alterations in the patient's menstrual bleeding pattern. Moreover, if pregnancy occurs while an intrauterine device (IUD) is inserted, there is a higher probability of encountering an ectopic pregnancy or septic abortion [54]. Noticeable discrepancies in the modification of bleeding patterns can be detected when comparing the copper IUD and levonorgestrel IUD. The copper intrauterine device (IUD) often causes a rise in menstrual flow, resulting in a heavier flow, and sometimes leads to a longer duration of menstruation [45]. Conversely, the levonorgestrel intrauterine device (IUD) induces a decrease in the quantity of monthly bleeding and might potentially lead to complete cessation of menstrual flow. This is because progesterone has the capacity to restrict the expansion of the endometrium [55]. A similar occurrence can also be witnessed with the levonorgestrel intrauterine devices (IUDs) administered at lesser dosages. However, a small number of individuals may encounter atypical bleeding and/or spotting as a result of reduced progesterone levels [37,56].

There is a continuous and unresolved controversy regarding the administration of medicines prior to and during the procedure in order to control discomfort. The study focused on evaluating the efficacy of various oral analgesics, including ibuprofen, naproxen, and tramadol. It was found that administering naproxen or tramadol prior to implantation had specific benefits [57]. Moreover, the effectiveness of misoprostol in promoting cervical dilation and insertion has been examined in nulliparous women, although no beneficial benefits were detected. The postponement of IUD placement was considered harmful [57]. However, in situations where a patient has previously encountered difficult insertions, it may be beneficial to take misoprostol [57]. The effectiveness of Nitroprusside as a pain reliever was examined, but no therapeutic benefit was seen with this treatment [58]. Topical anesthetics, which come in the form of creams and gels, have been proven to effectively reduce the discomfort caused by the implantation of a tenaculum. Nevertheless, they do not offer any analgesic effect during uterine sounding or IUD implantation [59]. The effectiveness of paracervical blocks has been studied for both IUD insertion and other cervical procedures. The effectiveness of these blocks for regular IUD implantation is uncertain due to conflicting results [58]. Empirical research indicates that buffered 1% lidocaine blocks are more effective than nonbuffered lidocaine in reducing discomfort during uterine sounding and IUD implantation. The blocks are located at the 4 and 8 o'clock positions in nulliparous people [60].

**Method or therapy**

1. Confirm a negative outcome of a pregnancy test.

2. Obtain clear and voluntary permission after presenting essential information.

3. Instruct the patient to assume a dorsal lithotomy position.

4. Employ gloved hands to perform a bimanual examination to determine the position of the uterus, whether it is anteverted or retroverted.

5. Insert a speculum and identify the cervix.

6. Employ a washing solution, typically povidone-iodine, to sanitize the cervix and vaginal fornices. For patients who have an allergy to iodine or shellfish, it is advisable to use chlorhexidine gluconate.

7. If you like, now is the suitable time to consider the insertion of a paracervical block or the application of anesthetic gel, as described earlier.

8. Proceed to use aseptic gloves and utilize a sterile single-tooth tenaculum to grasp the front border of the cervix and apply gentle pressure to align the cervical canal and uterine cavity. If the uterus is retroverted, it can be beneficial to grasp the posterior lip of the cervix.

9. Employ a sterile uterine sound to determine the exact measurement of the depth of the uterine cavity, often ranging from 6cm to 9cm. Insertion of an intrauterine device (IUD) is contraindicated when the cervical length measures less than 6 cm. If encountering difficulty in inserting the uterine sound, it is advisable to employ cervical dilators as a solution. When cervical dilators are required, it is recommended to provide a paracervical block.

10. Once the uterine depth has been determined, follow the instructions provided with the specific intrauterine device (IUD) for implantation.

11. Once the IUD has been inserted and the threads are visible, utilize sharp scissors to cut the strings to a length ranging from 3 cm to 4 cm. Ensure that you document this measurement in the chart.

12. Remove the tenaculum and confirm that there is no bleeding at the tenaculum site, then take out the speculum.

13. Arrange a further consultation with the patient within a period of 4-6 weeks to conduct a comprehensive assessment and validate the accurate alignment [36].

**After the IUD has been put for the prescribed period of time, it is essential to remove the IUD. If the patient desires to pursue further contraception, it is permissible to both extract and insert an intrauterine device (IUD) on the same day. The process of IUD removal entails the subsequent actions:**

1. Obtain clear and voluntary permission following the provision of pertinent information.

2. Direct the patient to place themselves in a dorsal lithotomy posture.

With gloved hands, cautiously insert the speculum to precisely locate and identify the cervix and IUD strings. In order to locate IUD strings that are not immediately apparent, gently rotate a cytobrush within the os.

4. Utilize ring forceps to securely grasp the strings of the intrauterine device (IUD).

5. Gently exert pressure on the IUD strings to remove the device from the uterus.

6. Ensure the soundness of the intrauterine device (IUD) and ascertain the absence of any missing components [36].

**Complexities**

When advising patients about the risks of IUD insertion, it is crucial to acknowledge that certain factors can lead to unfavorable or unforeseen results. A study conducted by researchers examined the ability to anticipate complications by analyzing different attributes of patients and healthcare providers [46]. Health care workers with limited competence and nulliparous women are more susceptible to facing difficulties or being unable to put an intrauterine device (IUD) [46]. Women who have never given birth (nulliparous women) are more susceptible to encountering problems with the widening of the cervix and symptoms of slow heart rate and fainting (bradycardia/vasovagal symptoms), which can be related to the manipulation of the cervix [46]. Moreover, older women had a greater occurrence of issues associated with proper cervical dilatation [46]. The competence and expertise of the provider performing the insertion were protective in all of these instances [46]. Hence, as a component of the consent procedure, it would be prudent to provide patients with guidance regarding their particular vulnerabilities, taking into account their unique medical background.

The procedure of IUD insertion is associated with minimal complications. The primary complication frequently observed is the displacement or inadvertent removal of the intrauterine device (IUD) following its insertion, typically within the initial three months of placement [61]. Furthermore, there is a heightened likelihood of expulsion if inserted subsequent to vaginal delivery or following an abortion [41, 42]. Administering intrauterine devices (IUDs) to patients soon after childbirth offers a significant advantage as it mitigates the risk of unintended pregnancies for those who may not attend a postpartum visit for IUD implantation [41].

The most concerning side effect for a patient is an undesired pregnancy. Although a tiny percentage of women may become pregnant while using an intrauterine device (IUD), this is far from the norm. The pregnancy rate with the copper IUD is around 0.6%, and with the 20 mg levonorgestrel IUD it's about 0.2% [48].

As an added precaution, uterine perforation is a real possibility after IUD installation for a small percentage of individuals. There is inconclusive evidence about how often this occurs, and it is not always possible to notice the initial puncture when inserting the device [62]. The risk of perforation is somewhat higher with the levonorgestrel intrauterine device (IUD) compared to the copper IUD, according to research. It should be noted, however, that the researchers in this study used the larger levonorgestrel device [62].

When interacting with the cervix, vasovagal symptoms, which can cause bradycardia, can occur during both the insertion and removal of intrauterine devices (IUDs). The symptoms of these patients should dictate the course of treatment. Women who have never given birth before or who feel a lot of pain throughout the procedure are more likely to develop these symptoms [63].

**Relevance to healthcare**

Within the US, one can find intrauterine devices (IUDs) that contain levonorgestrel and one that contains copper. In order to avoid becoming pregnant, these two kinds of devices work in different ways. A copper intrauterine device (IUD) can prevent sperm from migrating or surviving inside the uterus by triggering a localized cytotoxic inflammatory response [64]. This is why, when put within five days of an unprotected sexual encounter, copper IUDs provide excellent emergency contraception [64]. The endometrium is inhibited in its growth by the actions of progesterone, which the intrauterine devices (IUDs) containing levonorgestrel do. Estradiol is produced by the ovary, but the endometrium becomes resistant to it [38]. Furthermore, levonorgestrel hinders sperm motility and prevents conception by making cervical mucus more viscous [38]. These devices are often the best choice for women trying to avoid getting pregnant because they work, are reliable, and can be reversed. For menorrhagia treatment and endometrial protection during hormone replacement therapy, intrauterine devices (IUDs) with high doses of levonorgestrel are also beneficial. An advantage of intrauterine device insertion (IUD) is that it can be done within 10 minutes of placenta delivery, right after childbirth. Both the effectiveness of the contraceptive method and the rate of patient adherence are greatly improved by this.

**Improving the Results of Healthcare Teams**

The availability of several forms of long-acting reversible contraception (LARC) has been greatly improved in recent years. Still, some challenges remain, especially for young girls and women who have never had a child. Some medical professionals have not had enough training to properly instruct their teenage and other nulliparous patients on how to use long-acting reversible contraception (LARC). Because of their reversibility, effectiveness, and high patient satisfaction rate, there is strong evidence to promote these techniques in these populations. Also, teens and women who have never had children still face challenges such not knowing how to use the contraceptive device or being uncomfortable with it, the high cost of the device and the procedure, parental opposition, and not knowing who would be providing the consultation. Despite this, a large body of evidence shows that when women are informed about all of their contraceptive options and are not pressured about cost, 67% of women choose a long-acting reversible contraceptive (LARC), with 56% choosing an intrauterine device (IUD) in particular [50]. Therefore, it is critical for healthcare providers to stay updated on the current guidelines about improving patients' access to necessary healthcare. Because of their increased risk of pelvic inflammatory disorder—which might lead to infertility in the future—previous research has shown that nulliparous women should not be started on intrauterine devices (IUDs). However, further research has proven that these devices are safe for women who are not pregnant and has cast doubt on these claims [65]. Adolescents should use long-acting reversible contraception (LARC), especially intrauterine devices (IUDs), according to multiple prestigious medical organizations [49]. These organizations include the American College of Obstetrics and Gynecology, the American Academy of Pediatrics, the CDC, and the Society for Family Planning. Intrauterine devices (IUDs) have a high success rate of over 96% on the first attempt, which is higher than that of women who have given birth, and there is significant evidence to support their effectiveness in these patients. In addition, the two levonorgestrel IUDs with the smaller diameter may be useful if concerns about placing an IUD into a woman who has never given birth are present [49].

**Conclusion:**

The exploration of Intrauterine Devices (IUDs) reveals a dynamic landscape shaped by continuous development, nuanced advantages, inherent disadvantages, and a spectrum of diverse applications. From their historical roots to recent advancements, IUDs have evolved into a pivotal component of reproductive healthcare, offering a range of benefits tempered by challenges and ongoing research opportunities. The developmental trajectory of IUDs underscores the commitment to refining contraceptive methods. Advances in materials, design, and hormonal formulations aim to enhance user experience, minimize side effects, and extend the duration of contraceptive efficacy. User-centric approaches and customization, coupled with digital integration for monitoring, signify a shift towards more personalized and technologically-driven solutions. The advantages of IUDs, including high efficacy, long-term reversible contraception, and potential therapeutic applications, position them as versatile tools in reproductive healthcare. However, the exploration of their advantages must be accompanied by a recognition of the associated disadvantages, such as insertion discomfort, potential side effects, and misconceptions that may impact user acceptance. Diverse applications beyond contraception, including the management of gynecological conditions, underscore the expanding role of IUDs in women's health. As research explores their efficacy in addressing conditions like endometriosis and heavy menstrual bleeding, IUDs stand poised to contribute significantly to comprehensive gynecological care. Global health initiatives aimed at improving access to IUDs highlight the importance of making these devices available to a broad spectrum of women, overcoming economic, cultural, and logistical barriers. The integration of fertility awareness features further enhances their relevance, empowering individuals to make informed decisions about family planning. In conclusion, the exploration of Intrauterine Devices reveals a complex and evolving narrative within the realm of reproductive healthcare. The ongoing commitment to research and innovation underscores the potential for IUDs to continue playing a crucial role in addressing diverse aspects of women's health. As the field progresses, fostering awareness, addressing misconceptions, and promoting accessibility will be key to maximizing the benefits of IUDs and ensuring their positive impact on global reproductive health.

**Future Scope of Intrauterine Devices (IUDs):**

**1. Advanced Materials and Biocompatibility:**

Future research may focus on developing materials with enhanced biocompatibility, minimizing the risk of adverse reactions and discomfort associated with IUD use. Innovations in materials science could lead to the creation of biodegradable or bioresorbable IUDs, further improving user experience and reducing the environmental impact of device disposal.

**2. Precision Medicine and Personalized Contraception:**

The future of IUDs could see the integration of precision medicine approaches, tailoring contraceptive formulations to individual hormonal profiles and health needs. Personalized IUDs may become a reality, optimizing effectiveness while minimizing side effects based on the unique characteristics of each user.

**3. Innovations in Insertion Techniques:**

Advancements in insertion techniques may seek to reduce discomfort and streamline the process of IUD placement. Minimally invasive approaches, guided by imaging technologies or assisted by robotics, could enhance the accessibility and acceptability of IUDs, especially in settings where skilled healthcare professionals may be limited.

**4. Extended Duration and Remote Monitoring:**

Continued efforts to extend the duration of contraceptive efficacy may lead to IUDs with even longer lifespans, reducing the need for frequent replacements. Integration of remote monitoring technologies may become more sophisticated, allowing users and healthcare providers to track IUD status, hormonal levels, and overall health remotely, ensuring timely interventions and personalized care.

**5. Incorporation of Contraceptive Education and Counseling:**

Future IUDs may include built-in educational features to provide users with real-time information about the device, potential side effects, and fertility awareness. This could empower users to actively participate in their reproductive health decisions and address any concerns or misconceptions.

**6. Expanding Therapeutic Applications:**

Ongoing research may uncover additional therapeutic applications for IUDs beyond their current scope. Investigating their potential role in preventing specific gynecological cancers or managing hormonal imbalances could broaden the range of conditions that IUDs can effectively address.

**7. Global Health Initiatives and Accessibility:**

Future endeavors may concentrate on furthering global health initiatives to improve accessibility and affordability of IUDs, particularly in low-resource settings. Innovations in distribution channels, community-based education, and telemedicine could contribute to overcoming barriers and expanding access to quality reproductive healthcare.

**8. Collaborative Interdisciplinary Research:**

The interdisciplinary collaboration between researchers, clinicians, engineers, and data scientists is poised to drive future innovations in IUD development. By bringing together diverse expertise, researchers can explore novel avenues, combining medical, technological, and behavioral insights to create more effective and user-friendly IUD solutions.

**References**

1. Grimes DA, Lopez LM, Manion C, Schulz KF. Cochrane systematic reviews of IUD trials: lessons learned. Contraception 2007;75:S55–S59.
2. NICE. National Institute for Health and Clinical Excellence. Long-acting Reversible Contraception. 2005, www.nice.org.uk (25 September 2007, date last accessed).
3. Hubacher D, Reyes V, Lillo S, Pierre-Louis B, Zepeda A, Chen PL, Croxatto H. Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen. Hum Reprod 2006; 21:1467–1472.
4. Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004;190:50–54.
5. Luukkainen T. Levonorgestrel-releasing intrauterine device. Ann NY Acad Sci 1991;626:43– 49.
6. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception 2004;69: 407–412.
7. Population reference bureau: World population data sheet. 2011. [http:// www.prb.org/pdf11/2011population-data-sheet\_eng.pdf.
8. Central Statistical Agency (CSA) [Ethiopia] and ICF. Ethiopia Demographic and Health Survey 2006. Central Statistical Agency and ORC Marco; 2016.
9. Central Statistical Agency (CSA) [Ethiopia] and ICF. Ethiopia Demographic and Health Survey 2016: Key Indicators Report. CSA and ICF.
10. Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plan. 2014;45(3):301–14. <https://doi.org/10.1111/j.1728-4465.2014.00393.x>.
11. Singh S, Sedgh G, Hussain R. Unintended pregnancy: Worldwide levels, trends, and outcomes. Stud Fam Plan. 2010;41(4):241–50.
12. Gipson JD, Koenig MA, Hindin MJ. The efects of unintended pregnancy on infant, child, and parental health: a review of the literature. Stud Fam Plan. 2008;39(1):18–38.
13. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006;38(2):90–6.
14. Bearak J, Popinchalk A, Alkema L, Sedgh G. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health. 2018;6(4):e380–9.
15. Nations U. Trends in contraceptive use Worldwide. Obtenido de The Department of Economic and Social Afairs; 2015.
16. World Health Organization. Reproductive Health. Medical eligibility criteria for contraceptive use. World Health Organization; 2010.
17. Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, Gricar J. Cost efectiveness of contraceptives in the United States. Contraception. 2009;79(1):5–14.
18. Ethiopian Public Health Institute (EPHI) [Ethiopia] and ICF. Ethiopia mini demographic and health survey 2019: key indicators. EPHI and ICF; 2019.
19. Gbagbo FY, Kayi EA. Use and discontinuation of intrauterine contraceptive device in the Greater Accra region of Ghana. Contracept Reprod Med. 2018;3(1):8.
20. Postlethwaite D, Trussell J, Zoolakis A, Shabear R, Petitti D. A comparison of contraceptive procurement pre-and post-beneft change. Contraception. 2007;76(5):360–5.
21. Goodman S, Hendlish SK, Benedict C, Reeves MF, Pera-Floyd M, FosterRosales A. Increasing intrauterine contraception use by reducing barriers to post-abortal and interval insertion. Contraception. 2008;78(2):136–42.
22. Ortiz ME, Croxatto HB, Bardin CW. Mechanisms of action of intrauterine devices. Obstet Gynecol Surv 1996;51: S42–S51.
23. Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception 2007;75:S42–S51.
24. World Health Organization, Reproductive Health and Research. Medical Eligibility Criteria for Contraceptive Use, 3rd edn. Geneva: World Health Organization, 2004. http://www.who.int/reproductive\_health/ publications/mec/index.htm.
25. Barbosa I, Olsson SE, Odlind V, Goncalves T, Coutinho E. Ovarian function after seven years’ use of a levonorgestrel IUD. Adv Contracep 1995;11:85 –95.
26. Tredway DR, Umezaki CU, Mishell DR Jr, Settlage DS. Effect of intrauterine devices on sperm transport in the human being: preliminary report. Am J Obstet Gynecol 1975;123:734–735.
27. Koch UJ. Sperm migration in the human female genital tract with and without intrauterine devices. Acta Eur Fertil 1980;2:33– 60.
28. Jecht E, Berstein G. The influence of copper on the motility of human spermatozoa. Contraception 1973;7:381–401.
29. Kesseru E, Camacho-Ortega P. Influence of metals on in vitro sperm migration in the human cervical mucus. Contraception 1972;6:231– 240.
30. Jonsson B, Landgren B-M, Eneroth P. Effects of various IUDs on the composition of cervical mucus. Contraception 1991;43:447– 458.
31. Alvarez F, Brache V, Ferna´ndez E, Guerrero B, Guiloff E, Hess R, Salvatierra AM, Zacharias S. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril 1988;49:768– 773.
32. Kavanaugh ML, Jerman J. Contraceptive method use in the United States: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018 Jan;97(1):14-21. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959010/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29038071)]
33. Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, Whiteman MK. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep. 2016 Jul 29;65(4):1-66. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/27467319)]
34. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, Secura G. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011 May;117(5):1105-1113. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548669/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/21508749)]
35. Wildemeersch D, Hasskamp T, Nolte K, Jandi S, Pett A, Linden S, van Santen M, Julen O. A multicenter study assessing uterine cavity width in over 400 nulliparous women seeking IUD insertion using 2D and 3D sonography. Eur J Obstet Gynecol Reprod Biol. 2016 Nov;206:232-238. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/27768966)]
36. Johnson BA. Insertion and removal of intrauterine devices. Am Fam Physician. 2005 Jan 01;71(1):95-102. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/15663031)]
37. Apter D, Gemzell-Danielsson K, Hauck B, Rosen K, Zurth C. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril. 2014 Jun;101(6):1656-62.e1-4. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/24726226)]
38. Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception. 1995 Nov;52(5):269-76. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/8585882)]
39. Grandi G, Farulla A, Sileo FG, Facchinetti F. Levonorgestrel-releasing intra-uterine systems as female contraceptives. Expert Opin Pharmacother. 2018 May;19(7):677-686. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29637798)]
40. Goldstuck ND, Cheung TS. The efficacy of intrauterine devices for emergency contraception and beyond: a systematic review update. Int J Womens Health. 2019;11:471-479. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709799/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/31686919)]
41. Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol. 2010 Nov;116(5):1079-87. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104850/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/20966692)]
42. Grimes DA, Lopez LM, Schulz KF, Stanwood NL. Immediate postabortal insertion of intrauterine devices. Cochrane Database Syst Rev. 2010 Jun 16;(6):CD001777. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/20556754)]
43. Strasser J, Borkowski L, Couillard M, Allina A, Wood SF. Access to Removal of Long-acting Reversible Contraceptive Methods Is an Essential Component of High-Quality Contraceptive Care. Womens Health Issues. 2017 May-Jun;27(3):253-255. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/28476290)]
44. Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol. 2017 Nov;130(5):e251-e269. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29064972)]
45. Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device. Int J Womens Health. 2010 Aug 09;2:211-20. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2971735/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/21072313)]
46. Farmer M, Webb A. Intrauterine device insertion-related complications: can they be predicted? J Fam Plann Reprod Health Care. 2003 Oct;29(4):227-31. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/14662057)]
47. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, Simmons KB, Pagano HP, Jamieson DJ, Whiteman MK. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. 2016 Jul 29;65(3):1-103. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/27467196)]
48. Trussell J. Contraceptive failure in the United States. Contraception. 2011 May;83(5):397-404. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638209/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/21477680)]
49. ACOG Committee Opinion No. 735: Adolescents and Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol. 2018 May;131(5):e130-e139. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29683910)]
50. Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol. 2010 Aug;203(2):115.e1-7. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910826/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/20541171)]
51. Reeves MF, Zhao Q, Secura GM, Peipert JF. Risk of unintended pregnancy based on intended compared to actual contraceptive use. Am J Obstet Gynecol. 2016 Jul;215(1):71.e1-6. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/26805610)]
52. Min J, Buckel C, Secura GM, Peipert JF, Madden T. Performance of a checklist to exclude pregnancy at the time of contraceptive initiation among women with a negative urine pregnancy test. Contraception. 2015 Jan;91(1):80-4. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267981/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/25218500)]
53. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception. 2006 Feb;73(2):145-53. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/16413845)]
54. Intrauterine devices: an effective alternative to oral hormonal contraception. Prescrire Int. 2009 Jun;18(101):125-30. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/19637436)]
55. Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012 Mar;97(3):616-22.e1-3. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/22222193)]
56. Bahamondes L, Bahamondes MV. Assessment of the use of two new low-dose levonorgestrel-releasing intrauterine systems as contraceptives. Womens Health (Lond). 2012 May;8(3):235-8. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/22554171)]
57. Lopez LM, Bernholc A, Zeng Y, Allen RH, Bartz D, O'Brien PA, Hubacher D. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev. 2015 Jul 29;2015(7):CD007373. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580985/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/26222246)]
58. American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice; Long-Acting Reversible Contraceptive Expert Work Group. Committee Opinion No 672: Clinical Challenges of Long-Acting Reversible Contraceptive Methods. Obstet Gynecol. 2016 Sep;128(3):e69-77. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/27548557)]
59. Perez-Lopez FR, Martinez-Dominguez SJ, Perez-Roncero GR, Hernandez AV. Uterine or paracervical lidocaine application for pain control during intrauterine contraceptive device insertion: a meta-analysis of randomised controlled trials. Eur J Contracept Reprod Health Care. 2018 Jun;23(3):207-217. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29792756)]
60. Levine EM, Fernandez CM. Paracervical Block for Intrauterine Device Placement Among Nulliparous Women: A Randomized Controlled Trial. Obstet Gynecol. 2019 Jan;133(1):189. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/30575660)]
61. Aisien AO. Intrauterine contraceptive device (IUCD): acceptability and effectiveness in a tertiary institution. Afr J Med Med Sci. 2007 Sep;36(3):193-200. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/18390056)]
62. Barnett C, Moehner S, Do Minh T, Heinemann K. Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study. Eur J Contracept Reprod Health Care. 2017 Dec;22(6):424-428. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/29322856)]
63. Chi IC, Wilkens LR, Siemens AJ, Lippes J. Syncope and other vasovagal reactions at interval insertion of Lippes Loop D--who is most vulnerable? Contraception. 1986 Feb;33(2):179-87. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/3516567)]
64. Bahamondes L, Fernandes A, Monteiro I, Bahamondes MV. Long-acting reversible contraceptive (LARCs) methods. Best Pract Res Clin Obstet Gynaecol. 2020 Jul;66:28-40. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/32014434)]
65. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992 Mar 28;339(8796):785-8. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/1347812)]
66. Teal SB, Romer SE, Goldthwaite LM, Peters MG, Kaplan DW, Sheeder J. Insertion characteristics of intrauterine devices in adolescents and young women: success, ancillary measures, and complications. Am J Obstet Gynecol. 2015 Oct;213(4):515.e1-5. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/26116873)]